Selling or partnering your medical biology laboratory: what remains to be decided for independent biologists

Until the late 2000s, a clinical laboratory in France was handed on between biologists: a departing partner sold their shares to a young colleague, often their former assistant. The ordinance of 13 January 2010, known as the Ballereau ordinance, then the law of 30 May 2013 changed the picture by requiring accreditation of all tests, organising multi-site laboratories and regulating capital ownership. ¹ The cost of compliance, price pressure and the arrival of private capital did the rest: the sector concentrated at a speed few health professions have seen, with regional then national networks organised around technical platforms and collection sites.

Medical biology has thus become one of the most advanced examples of consolidation in healthcare, and the stakes are shifting to the quality of the network, technical platforms and investment capacity. A biologist thinking about the future of their laboratory no longer faces a colleague as buyer, but structured groups, which changes their options, timing and preparation.

A €5 billion market in the hands of a few groups

Private medical biology represented €5.1 billion of reimbursable spending in 2024, against €4.5 billion in 2013, an average increase of 1.1% a year according to the joint report by the French General Inspectorate of Finance (IGF) and General Inspectorate of Social Affairs (IGAS) published in 2025. ² This modest growth in value hides a strong rise in volumes, offset by price cuts: tariffs fell by around 15% between 2013 and 2023 according to the health ministry's statistics directorate DREES. ² The network remains highly accessible: 99.8% of the population lives within thirty minutes of a collection site, even though legal entities have largely merged. ^2,3

The structure of the sector has been transformed. The number of legal entities fell from 2,625 at the end of 2009 to 377 at the end of 2021 according to the French Senate report on the financialisation of healthcare, then to 284 laboratories in 2023 according to the IGF-IGAS mission, for around 4,000 sites. ^2,4 Six groups, Biogroup, Cerba, Inovie, Synlab, Eurofins and Unilabs, hold 74% of sites, whereas in 2010 six sites in ten still belonged to an entity with fewer than ten employees. ^2,5 Concentration has allowed analysers, logistics, purchasing and information systems to be pooled; it also raises questions of competition, sovereignty and local access that the authorities follow closely. Profitability remains high for a healthcare sector, with EBITDA at 17% of revenue in 2023. ² Recurring revenue, solid margins and a perimeter still to consolidate: that is what continues to attract capital.

The drivers of concentration

The restructuring rests on structural factors that have not finished producing their effects.

Accreditation and the cost of quality. The 2013 law led to accreditation of 100% of tests, now mandatory across all lines of scope. ¹ Quality management, metrology, IT, dedicated staff: compliance has a fixed cost that only large volumes can amortise. This was the first factor pushing small laboratories to combine.
Permanent price pressure. For around ten years, multi-year agreements with the national health insurance fund have limited growth in the budget envelope to a few tenths of a point a year, with additional volumes offset by lower test fees. ⁶ In August 2024, the health insurance union Uncam unilaterally decided on a cut of around 10% in tariffs, before an agreement signed on 20 December 2024 with three unions, including SDBIO, froze the fee schedule until the end of 2026. ^6,7,8 Each tariff discussion reinforces the importance of productivity and size; an independent absorbs these cuts alone.
Industrialisation of the technical platform and the network. High-throughput analysers, analytical lines, information systems interfaced with prescribers: biology has become a capital-intensive activity, and analysis is migrating to centralised platforms only groups can finance. The logic is also territorial: a sufficient density of collection sites improves sample collection and platform utilisation, which explains why groups seek to densify their network area by area.
Technology investment. Specialised biology, genomics, sequencing, AI applied to validation, cybersecurity of information systems and health data: the resources needed to stay at the state of the art are growing faster than tariffs.
Biologist demographics. France had 9,941 medical biologists on 1 January 2023, down 7% since 2014, and self-employed biologists' incomes have fallen by around a third since 2010. ² For a 55-year-old partner, carrying new investments alone and recruiting increasingly scarce young biologists weighs on the decision; the transfer of stakes continues to fuel capital reorganisations.
Available capital. Since the 1990 law, non-biologist investors may hold up to 25% of the capital of a biologists' company, and holding structures have allowed funds to take economic control of entire groups. ^5,9 The September 2024 Senate report considers these rules emptied of meaning by holding structures and proposes enshrining the notion of effective control in law. ^4,9

Who buys laboratories today

The legal framework shapes the form of transactions. Biologists practising in the company must keep a majority of the capital and voting rights, non-professionals may not hold more than 25%, and the 2013 law prohibited separating capital from voting rights. ^1,4 Regional health agencies (ARS) can oppose an acquisition when the laboratory would exceed 25% of the tests in an area, which makes a prior analysis of the local landscape essential in already highly concentrated territories. ² There are four buyer profiles.

Fund-backed national groups. They acquire laboratories that complete or densify their network and attach collection sites to their technical platforms. Selling biologists often become minority partners in the local company, sometimes shareholders in the top holding. The IGF-IGAS mission notes, however, that the six main groups are weakened by high debt, which makes them more selective in their acquisitions. ^2,3
Regional biologist groups. In several regions, biologists have grouped into structures of several dozen sites, which make targeted combinations before reaching a larger size. Inovie, a group in the south of France where four funds led by Ardian invested at the end of 2020 with the favourable vote of the vast majority of its 380 partner biologists, illustrates a path where professionals keep a central role in governance. ¹⁰
Specialist players. In anatomic pathology, genetics, reproductive biology or specialised microbiology, players seek expertise rather than volume, with an interest distinct from that of general networks.
Neighbouring colleagues and reorganisations between biologists. Combining independents in the same territory remains possible to reach critical mass while keeping control among biologists, and an internal capital reorganisation can organise succession and governance without a full sale to an outside group.

The available perimeter is shrinking and large groups are becoming more selective: a well-positioned independent is all the more sought after, but must demonstrate its value rigorously.

What this changes for the partner biologist

This diversity of buyers is matched by a diversity of structures.

A full sale suits partners close to retirement, with a period of one to three years practising within the group to ensure continuity.
A partnership with reinvestment is for partners, whatever their age, who still have several years of activity ahead: they sell a majority of their shares, reinvest part of the price in the group's holding and share in the value created at the next transaction, while continuing to practise.
A combination between colleagues creates a regional group controlled by biologists and organises succession, without an outside investor or with a minority one.
A capital reorganisation between partners, such as an OBO, lets the most senior monetise part of their shares, financed by debt, and bring young biologists into the capital.

The choice between these structures depends first on each partner's professional plans: who wants to stay, for how long, on what terms, and who is preparing to leave. These answers shape the possible structure of the deal. Whatever the structure, in an already consolidated market, a buyer's interest depends on location, authorisations, the volume brought to the network and synergies with its existing platforms. Here is what buyers look at first.

Locations. Density and quality of collection sites, locations, geographic complementarity with the buyer's network and the competitive situation of the area with regard to the 25% threshold monitored by the ARS.
Volumes and prescribers. Stability of test flows, diversity of community prescribers, weight of contracts with clinics and care homes, local demographic trends.
Technical platform and information system. Capacity, level of automation, specialties performed on site, age of analysers and upcoming investment needs shape the buyer's industrial plan, which will decide whether to keep the platform or attach the sites to its own.
The biologist team and medical governance. Number of biologists, age profile, on-call organisation, technical managers and the collective ability to retain key professionals after the deal are major topics.
Quality and compliance. Accreditation status and any non-conformities, quality management system, traceability, health data protection and regulatory compliance form the core of due diligence.
Contracts and leases. Site leases, contracts with healthcare facilities, sample transport agreements and partners' agreements are reviewed to check business continuity.
Real profitability. Once partners' pay is normalised and exceptional effects, notably from the Covid period, are adjusted, recurring margin is the basis for discussion.

You are thinking of selling: is this the right moment for you?

This is the first question we ask, and the answer is not the same for everyone. The right moment for a sale or partnership is never automatically "right now", even in a sector where buyers are active. It depends on two things: you, meaning your life plans, personal horizon and wealth objectives, and your laboratory, meaning its ability to realise today all the value it holds. We encounter two situations.

Your laboratory is almost ready. Accreditation is complete, prescribers are diversified, the technical platform is recent, the team is stable and profitability is readable excluding the Covid effect. Or you want your laboratory to become part of a larger project, that of a large group, often under LBO, that brings analysers, information systems, expertise and the resources to absorb the next tariff cuts, which is reassuring for you and for your teams. In this case, a few weeks of preparation are enough to go to market. The current context, with several groups competing for the last independent perimeters, then works in your favour.
Your laboratory needs time. One clinic accounts for an excessive share of activity and its contract is coming to an end, accreditation has unresolved non-conformities, margins have been hit by a recent investment or the end of Covid testing. Selling remains possible, but it means accepting a discount and less favourable terms. We will then tell you frankly that it is better to spend several months, sometimes a few years, working on these points, and we can support you through that phase before launching the transaction when you are truly ready.

The workstreams that make the difference in biology are well known: map sites, volumes, prescribers and platform capacity, close accreditation gaps, secure contracts with facilities and site leases, plan the renewal of the technical platform, normalise partners' pay, retain biologists and technical managers, and prepare the legal side, notably partners' agreements. The timetable must also fit with accreditation deadlines and investment projects, so that an urgent financing need does not dictate the choice of partner. Depending on your starting point, these workstreams take a few weeks or a few years.

The benefit of talking early, even without being sure you want to sell, is knowing which of these two situations you are in, and deciding with full knowledge rather than under the pressure of an approach, a partner's departure or a new tariff cut.

Facing groups that complete dozens of acquisitions a year with dedicated teams, a biologist negotiating alone is rarely on an equal footing. The value of a laboratory is not just a headline price: it depends on the deal structure (cash portion, earn-out, reinvestment), the warranties requested, partners' practice conditions and the future of the teams. Two offers for the same amount can mean very different things.

The role of an independent M&A adviser is to value the laboratory objectively, identify all relevant buyers, national groups, regional groups, specialist players, colleagues and investors, put them in competition in a structured and confidential process, and negotiate terms beyond price alone. This competition protects the seller: it lets them compare genuinely different projects and choose the one that suits them.

Frequently asked questions

Is medical biology still a consolidation market?

Yes, but the sector is already highly concentrated: six groups hold nearly three quarters of sites. ² Deals are now driven by territorial coverage, synergies between technical platforms and specialised expertise rather than a race for volume alone. A well-located independent laboratory remains sought after, all the more so as several groups compete for the last available perimeters.

Can an investment fund buy a medical biology laboratory in France?

Not directly as a majority owner. Biologists practising in the professional company (SEL) must keep a majority of the capital and voting rights, and non-professionals may not hold more than 25%. ¹ In practice, funds economically control the large groups through holding companies, which the Senate criticised in 2024. For a selling biologist, the buyer is therefore a biologists' company backed by a group, in which they often remain a minority partner.

Can you sell your laboratory and continue to practise as a biologist?

Yes, it is the rule rather than the exception. Groups want biologists to stay to ensure medical continuity and the relationship with prescribers. Depending on each person's age and plans, the partner practises for one to three years after a full sale, or continues long term after a partnership with reinvestment in the group's holding. Practice conditions and pay are negotiated alongside the price.

Who buys clinical laboratories in France?

Fund-backed national groups such as Biogroup, Cerba, Inovie, Synlab, Eurofins or Unilabs carry out most deals to densify their network. They are joined by regional biologist groups, specialist players in anatomic pathology, genetics or reproductive biology, and neighbouring colleagues who combine to reach critical mass while keeping control among biologists.

How long does it take to sell a medical biology laboratory?

Generally six to twelve months between launching the process and signing: preparing the file, confidentially approaching buyers, offers, quality, financial and legal due diligence, negotiation, then formalities with the regional health agency and the professional order. Analysis of the 25% test threshold in the area and the agreement of all partners can lengthen the timetable. Upstream preparation can take from a few weeks to several years.

What are the main due diligence topics when selling a laboratory?

Accreditation status and any non-conformities, the quality system and traceability, volumes and the spread of prescribers, contracts with clinics, the technical platform and information system, site leases, governance and stability of the biologist team, regulatory compliance and real profitability after normalising partners' pay.

Can a small independent laboratory still interest a group?

Yes, when it brings a geographic presence the group does not cover, complementary volumes for an existing platform or a specific expertise. In a market where available perimeters are becoming scarce, a well-positioned independent is even sought by several groups at once, provided it can demonstrate its value with precise data on its sites, prescribers and quality.

Why put several groups in competition to sell your laboratory?

Because projects differ on much more than price: keeping or attaching the technical platform, the future of sites and teams, biologists' practice conditions and pay, the share reinvested in the holding, warranties requested. A confidential process approaching several buyers in parallel allows these offers to be compared on a like-for-like basis and strengthens the selling partners' negotiating position.

Public sources consulted

Ordre national des pharmaciens, Dossier « Biologie médicale : la réforme », Le journal n° 28 (septembre 2013) : https://apiop.ordre.pharmacien.fr/content/download/113103/617676/version/1/file/J28_Dossier-BiologieMedicalereforme.pdf (high reliability)
IGF et IGAS, Pertinence et efficience des dépenses de biologie médicale, rapport n° 2024-M-055-02 / 2024-079R1 (mai 2025, publié juillet 2025) : https://igas.gouv.fr/sites/igas/files/2025-07/Rapport%20Igas%20Pertinence%20et%20efficience%20des%20d%C3%A9penses%20de%20biologie%20m%C3%A9dicale%20%281%29_0.pdf (high reliability)
IGAS, Pertinence et efficience des dépenses de biologie médicale, présentation du rapport IGAS-IGF (15 juillet 2025) : https://www.igas.gouv.fr/pertinence-et-efficience-des-depenses-de-biologie-medicale-0 (high reliability)
Sénat, Rapport d'information sur la financiarisation de l'offre de soins, C. Imbert, B. Jomier, O. Henno (25 septembre 2024) : https://senat.fr/rap/r23-776/r23-7761.pdf (high reliability)
DGS, DGOS et DSS, État des lieux de la réforme de la biologie médicale (2022) : https://peps.sante.gouv.fr/actu/2024/24_dgs-dgos-dss_etat-des-lieux-reforme-biologie_pj3.pdf (high reliability)
Sénat, Question écrite n° 00605 de Mme Anne-Sophie Romagny sur les baisses de tarifs de la biologie médicale et réponse du ministère (octobre 2024, réponse juin 2025) : https://www.senat.fr/questions/base/2024/qSEQ241000605.html (high reliability)
Le Quotidien du Médecin, « Un plan mortifère » : les biologistes furieux face à la nouvelle baisse envisagée de leurs tarifs (31 juillet 2024) : https://cardiologie.lequotidiendumedecin.fr/liberal-soins-de-ville/assurance-maladie/un-plan-mortifere-les-biologistes-furieux-face-la-nouvelle-baisse-envisagee-de-leurs-tarifs-en (good reliability)
Caisse d'Epargne, Biologistes : signature d'un accord avec la CNAM (janvier 2025) : https://www.caisse-epargne.fr/professionnels/conseils/biologistes-accord-cnam/ (moderate reliability)
Ordre national des pharmaciens, La financiarisation de l'offre de soins : les enjeux pour la pharmacie, lettre institutionnelle n° 21 (janvier 2025) : https://www.ordre.pharmacien.fr/mediatheque/fichiers/documents-pages/la-financiarisation-de-l-offre-de-soins-les-enjeux-pour-la-pharmacie (high reliability)
Le Quotidien du Médecin, Le fonds Ardian prend le contrôle du groupe Inovie (27 novembre 2020) : https://gynecologie-obstetrique.lequotidiendumedecin.fr/le-fonds-ardian-prend-le-controle-du-groupe-inovie (good reliability)